Y-mAbs Therapeutics, Inc.

NasdaqGS:YMAB Stock Report

Mkt Cap: US$195.2m

Y-mAbs Therapeutics Past Performance

How has Y-mAbs Therapeutics performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-24.2%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: YMAB is currently unprofitable.

Growing Profit Margin: YMAB is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: YMAB is unprofitable, and losses have increased over the past 5 years at a rate of 24.2% per year.

Accelerating Growth: Unable to compare YMAB's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: YMAB is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (53%).


Return on Equity

High ROE: YMAB has a negative Return on Equity (-123.84%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies